C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 231/56 (2006.01) A61K 31/416 (2006.01) A61P 25/00 (2006.01)
Patent
CA 2341612
A chemical compound of formula (I) wherein R1 to R3 are independently selected from hydrogen and alkyl; R4 to R7 are independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, amino, monoalkylamino, dialkylamino, alkoxy, aryloxy, alkylthio, arylthio, arylsulfoxyl, arylsulfonyl, alkylsulfoxyl, alkylsulfonyl, nitro, cyano, carboxaldehyde, alkylcarbonyl, arylcarbonyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonylamino, aminocarbonyloxy, monoalkylaminocarbonyloxy, dialkylaminocarbonyloxy, monoalkylaminocarbonylamino and dialkylaminocarbonylamino; and R8 is selected from alkyl and alkoxy, and pharmaceutically acceptable salts and prodrugs thereof, and the use thereof in therapy, particularly for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and particularly for the treatment of obesity.
La présente invention concerne un composé chimique de formule (I) dans lequel R¿1? à R¿3? sont choisis de manière indépendante parmi un groupe hydrogène et un groupe alkyle, R¿4? à R¿7? sont choisis de manière indépendante parmi un groupe hydrogène, halogène, hydroxy, alkyle, aryle, amino, monoalkylamino, dialkylamino, alkoxy, aryloxy, alkylthio, arylthio, arylsulfoxyle, arylsulfonyle, alkylsufoxyle, alkylsulfonyle, nitro, cyano, carboxaldéhyde, alkylcarbonyle, arylcarbonyle, aminocarbonyle, monoalkylaminocarbonyle, dialkylaminocarbonyle, alkoxycarbonylamino, aminocarbonyloxy, monoalkylaminocarbonyloxy, dialkylaminocarbonyloxy, monoalkylaminocarbonylamino and dialkylaminocarbonylamino, et R¿8? est choisi parmi un groupe alkyle and alkoxy, ainsi que des sels acceptables sur le plan pharmaceutique et des promédicaments de ces composés. L'invention concerne aussi l'utilisation de ces composés en thérapie, destinés particulièrement au traitement de troubles du système nerveux central, de dommages du système nerveux central, de troubles cardiovasculaires et gastro-intestinaux, de diabète insipide, et de l'apnée du sommeil, et en particulier au traitement de l'obésité.
Adams David Reginald
Bentley Jonathan Mark
George Ashley Roger
Hamlyn Richard John
Roffey Jonathan Richard Anthony
Kirby Eades Gale Baker
Vernalis Research Limited
LandOfFree
Indazole derivatives with 5-ht2 receptor activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indazole derivatives with 5-ht2 receptor activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indazole derivatives with 5-ht2 receptor activity will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1778472